Tags

Type your tag names separated by a space and hit enter

Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis.
Aliment Pharmacol Ther. 2006 Jul 01; 24(1):111-6.AP

Abstract

BACKGROUND

Case reports have suggested that the use of newer cyclo-oxygenase-2 selective inhibitors may cause acute pancreatitis, but there has been no formal study of the association.

AIM

To assess the relationship between the use of cyclo-oxygenase-2 inhibitors and other non-steroidal anti-inflammatory drugs, and risk of acute pancreatitis.

METHODS

A population-based case-control study was conducted using hospital discharge and prescription data from Denmark. Using conditional logistic regression with adjustment for multiple covariates, we estimated the relative risk of acute pancreatitis for use of the cyclo-oxygenase-2 inhibitors celecoxib and rofecoxib and for other non-steroidal anti-inflammatory drugs.

RESULTS

A total of 3083 cases of acute pancreatitis and 30 830 population controls were identified. For current use the relative risk estimate for celecoxib was 1.4 (95% CI: 0.8-2.3) and for rofecoxib was 1.3 (95% CI: 0.7-2.3). The overall relative risk for other non-steroidal anti-inflammatory drugs was 2.7 (95% CI: 2.4-3.0) with a substantial variation in risk between the individual drugs. The highest relative risk was for diclofenac (odds ratio 5.0, 95% CI: 4.2-5.9) and the lowest for naproxen (odds ratio 1.1, 95% CI: 0.7-1.7).

CONCLUSION

Cyclo-oxygenase-2 selective inhibitors are associated with a lower risk of acute pancreatitis than most other non-steroidal anti-inflammatory drugs.

Authors+Show Affiliations

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus C, Denmark. hts@dce.au.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16803609

Citation

Sørensen, H T., et al. "Newer Cyclo-oxygenase-2 Selective Inhibitors, Other Non-steroidal Anti-inflammatory Drugs and the Risk of Acute Pancreatitis." Alimentary Pharmacology & Therapeutics, vol. 24, no. 1, 2006, pp. 111-6.
Sørensen HT, Jacobsen J, Nørgaard M, et al. Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. Aliment Pharmacol Ther. 2006;24(1):111-6.
Sørensen, H. T., Jacobsen, J., Nørgaard, M., Pedersen, L., Johnsen, S. P., & Baron, J. A. (2006). Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. Alimentary Pharmacology & Therapeutics, 24(1), 111-6.
Sørensen HT, et al. Newer Cyclo-oxygenase-2 Selective Inhibitors, Other Non-steroidal Anti-inflammatory Drugs and the Risk of Acute Pancreatitis. Aliment Pharmacol Ther. 2006 Jul 1;24(1):111-6. PubMed PMID: 16803609.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. AU - Sørensen,H T, AU - Jacobsen,J, AU - Nørgaard,M, AU - Pedersen,L, AU - Johnsen,S P, AU - Baron,J A, PY - 2006/6/29/pubmed PY - 2007/1/19/medline PY - 2006/6/29/entrez SP - 111 EP - 6 JF - Alimentary pharmacology & therapeutics JO - Aliment Pharmacol Ther VL - 24 IS - 1 N2 - BACKGROUND: Case reports have suggested that the use of newer cyclo-oxygenase-2 selective inhibitors may cause acute pancreatitis, but there has been no formal study of the association. AIM: To assess the relationship between the use of cyclo-oxygenase-2 inhibitors and other non-steroidal anti-inflammatory drugs, and risk of acute pancreatitis. METHODS: A population-based case-control study was conducted using hospital discharge and prescription data from Denmark. Using conditional logistic regression with adjustment for multiple covariates, we estimated the relative risk of acute pancreatitis for use of the cyclo-oxygenase-2 inhibitors celecoxib and rofecoxib and for other non-steroidal anti-inflammatory drugs. RESULTS: A total of 3083 cases of acute pancreatitis and 30 830 population controls were identified. For current use the relative risk estimate for celecoxib was 1.4 (95% CI: 0.8-2.3) and for rofecoxib was 1.3 (95% CI: 0.7-2.3). The overall relative risk for other non-steroidal anti-inflammatory drugs was 2.7 (95% CI: 2.4-3.0) with a substantial variation in risk between the individual drugs. The highest relative risk was for diclofenac (odds ratio 5.0, 95% CI: 4.2-5.9) and the lowest for naproxen (odds ratio 1.1, 95% CI: 0.7-1.7). CONCLUSION: Cyclo-oxygenase-2 selective inhibitors are associated with a lower risk of acute pancreatitis than most other non-steroidal anti-inflammatory drugs. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/16803609/Newer_cyclo_oxygenase_2_selective_inhibitors_other_non_steroidal_anti_inflammatory_drugs_and_the_risk_of_acute_pancreatitis_ L2 - https://doi.org/10.1111/j.1365-2036.2006.02959.x DB - PRIME DP - Unbound Medicine ER -